S&P 500   3,383.25 (+1.49%)
DOW   27,952.84 (+0.96%)
QQQ   272.58 (+2.79%)
AAPL   452.83 (+3.50%)
MSFT   210.04 (+3.27%)
FB   261.42 (+2.07%)
GOOGL   1,509.58 (+1.96%)
AMZN   3,166.51 (+2.79%)
NVDA   456.92 (+5.28%)
CGC   17.40 (+2.65%)
BABA   255.54 (+2.87%)
TSLA   1,552.82 (+12.98%)
GE   6.63 (-1.49%)
MU   48.58 (+1.72%)
AMD   82.44 (+7.23%)
T   30.20 (-0.26%)
F   7.11 (-1.66%)
ACB   9.86 (-1.60%)
GILD   68.89 (+1.16%)
NFLX   480.44 (+2.89%)
DIS   131.35 (+0.66%)
BAC   26.62 (-1.11%)
BA   173.96 (-3.43%)
S&P 500   3,383.25 (+1.49%)
DOW   27,952.84 (+0.96%)
QQQ   272.58 (+2.79%)
AAPL   452.83 (+3.50%)
MSFT   210.04 (+3.27%)
FB   261.42 (+2.07%)
GOOGL   1,509.58 (+1.96%)
AMZN   3,166.51 (+2.79%)
NVDA   456.92 (+5.28%)
CGC   17.40 (+2.65%)
BABA   255.54 (+2.87%)
TSLA   1,552.82 (+12.98%)
GE   6.63 (-1.49%)
MU   48.58 (+1.72%)
AMD   82.44 (+7.23%)
T   30.20 (-0.26%)
F   7.11 (-1.66%)
ACB   9.86 (-1.60%)
GILD   68.89 (+1.16%)
NFLX   480.44 (+2.89%)
DIS   131.35 (+0.66%)
BAC   26.62 (-1.11%)
BA   173.96 (-3.43%)
S&P 500   3,383.25 (+1.49%)
DOW   27,952.84 (+0.96%)
QQQ   272.58 (+2.79%)
AAPL   452.83 (+3.50%)
MSFT   210.04 (+3.27%)
FB   261.42 (+2.07%)
GOOGL   1,509.58 (+1.96%)
AMZN   3,166.51 (+2.79%)
NVDA   456.92 (+5.28%)
CGC   17.40 (+2.65%)
BABA   255.54 (+2.87%)
TSLA   1,552.82 (+12.98%)
GE   6.63 (-1.49%)
MU   48.58 (+1.72%)
AMD   82.44 (+7.23%)
T   30.20 (-0.26%)
F   7.11 (-1.66%)
ACB   9.86 (-1.60%)
GILD   68.89 (+1.16%)
NFLX   480.44 (+2.89%)
DIS   131.35 (+0.66%)
BAC   26.62 (-1.11%)
BA   173.96 (-3.43%)
S&P 500   3,383.25 (+1.49%)
DOW   27,952.84 (+0.96%)
QQQ   272.58 (+2.79%)
AAPL   452.83 (+3.50%)
MSFT   210.04 (+3.27%)
FB   261.42 (+2.07%)
GOOGL   1,509.58 (+1.96%)
AMZN   3,166.51 (+2.79%)
NVDA   456.92 (+5.28%)
CGC   17.40 (+2.65%)
BABA   255.54 (+2.87%)
TSLA   1,552.82 (+12.98%)
GE   6.63 (-1.49%)
MU   48.58 (+1.72%)
AMD   82.44 (+7.23%)
T   30.20 (-0.26%)
F   7.11 (-1.66%)
ACB   9.86 (-1.60%)
GILD   68.89 (+1.16%)
NFLX   480.44 (+2.89%)
DIS   131.35 (+0.66%)
BAC   26.62 (-1.11%)
BA   173.96 (-3.43%)
Log in

NYSEAMERICAN:CRMDCorMedix Stock Price, Forecast & News

$3.95
-0.15 (-3.66 %)
(As of 08/12/2020 02:23 PM ET)
Add
Compare
Today's Range
$3.91
Now: $3.95
$4.19
50-Day Range N/A
52-Week Range
$2.16
Now: $3.95
$8.64
Volume19,097 shs
Average Volume288,050 shs
Market Capitalization$103.20 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.
Read More
CorMedix logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.80 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:CRMD
Previous SymbolNYSEMKT:CRMD
CUSIPN/A
Phone+1-908-5179500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees22
Market Cap$103.20 million
Next Earnings Date11/12/2020 (Estimated)
OptionableOptionable
$3.95
-0.15 (-3.66 %)
(As of 08/12/2020 02:23 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CRMD News and Ratings via Email

Sign-up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











CorMedix (NYSEAMERICAN:CRMD) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of CorMedix?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CorMedix in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for CorMedix
.

When is CorMedix's next earnings date?

CorMedix is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for CorMedix
.

How were CorMedix's earnings last quarter?

CorMedix Inc. (NYSEAMERICAN:CRMD) released its earnings results on Monday, August, 10th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.24) by $0.10.
View CorMedix's earnings history
.

When did CorMedix's stock split? How did CorMedix's stock split work?

Shares of CorMedix reverse split before market open on Tuesday, March 26th 2019. The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 25th 2019. An investor that had 100 shares of CorMedix stock prior to the reverse split would have 20 shares after the split.

What price target have analysts set for CRMD?

2 Wall Street analysts have issued 1-year target prices for CorMedix's stock. Their forecasts range from $10.00 to $12.00. On average, they expect CorMedix's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 178.5% from the stock's current price.
View analysts' price targets for CorMedix
.

Has CorMedix been receiving favorable news coverage?

News articles about CRMD stock have been trending negative recently, according to InfoTrie. The research firm identifies negative and positive media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. CorMedix earned a coverage optimism score of -2.2 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near term.
View the latest news about CorMedix
.

Who are some of CorMedix's key competitors?

What other stocks do shareholders of CorMedix own?

Who are CorMedix's key executives?

CorMedix's management team includes the following people:
  • Mr. Khoso Baluch, CEO & Director (Age 61)
  • Mr. Robert W. Cook, Chief Financial Officer (Age 63)
  • Mr. John L. Armstrong Jr., Head of HR & Exec. VP of Technical Operations (Age 75)
  • Ms. Elizabeth Masson, Exec. VP & Head of Clinical Operations (Age 40)
  • Dr. Phoebe Mounts, Exec. VP & Gen. Counsel

What is CorMedix's stock symbol?

CorMedix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CRMD."

Who are CorMedix's major shareholders?

CorMedix's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Steward Partners Investment Advisory LLC (0.31%), California Public Employees Retirement System (0.20%), Planning Directions Inc. (0.19%), Riversedge Advisors LLC (0.05%), SG Americas Securities LLC (0.05%) and State Board of Administration of Florida Retirement System (0.04%). Company insiders that own CorMedix stock include Hudson Executive Capital Lp, Janet Dillione, Jr John L Armstrong, Khoso Baluch, Mehmood Khan, Myron Kaplan, Phoebe Mounts, Robert W Cook and Steven W Lefkowitz.
View institutional ownership trends for CorMedix
.

Which institutional investors are selling CorMedix stock?

CRMD stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG.
View insider buying and selling activity for CorMedix
.

Which institutional investors are buying CorMedix stock?

CRMD stock was acquired by a variety of institutional investors in the last quarter, including Planning Directions Inc., California Public Employees Retirement System, SG Americas Securities LLC, State Board of Administration of Florida Retirement System, Avestar Capital LLC, Steward Partners Investment Advisory LLC, and Riversedge Advisors LLC. Company insiders that have bought CorMedix stock in the last two years include Hudson Executive Capital Lp, Janet Dillione, Jr John L Armstrong, Khoso Baluch, Mehmood Khan, Myron Kaplan, Phoebe Mounts, Robert W Cook, and Steven W Lefkowitz.
View insider buying and selling activity for CorMedix
.

How do I buy shares of CorMedix?

Shares of CRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CorMedix's stock price today?

One share of CRMD stock can currently be purchased for approximately $3.95.

How big of a company is CorMedix?

CorMedix has a market capitalization of $103.20 million. CorMedix employs 22 workers across the globe.

What is CorMedix's official website?

The official website for CorMedix is www.cormedix.com.

How can I contact CorMedix?

CorMedix's mailing address is 1430 US Highway 206 Ste 200, BEDMINSTER, NJ 07921-4602, United States. The biotechnology company can be reached via phone at +1-908-5179500.

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.